New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 11, 2012
05:31 EDTELN, BIIBBiogen, Elan TYSABRI data at ECTRIMS reaffirms positive effects for MS
Biogen Idec (BIIB) and Elan (ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28TH Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS, in Lyon, France, Oct. 10-13. The data will further establish the benefits of TYSABRI in reducing relapse rates and slowing disease progression.
News For BIIB;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
15:16 EDTBIIBBiogen sell off a buying opportunity, Barron's says
Biogen is down about 6% on the session after reporting Q1 results that missed expectations. The pullback represents a buying opportunity as the company's drug pipeline should fuel strong growth, Barron's says. Reference Link
09:28 EDTBIIBPiper says Biogen has 'long way to go' before being top pick again
Subscribe for More Information
09:20 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
07:40 EDTBIIBForward Pharma price target raised to $53 from $43 at Leerink
Subscribe for More Information
07:02 EDTBIIBBiogen reports Q1 Tecfidera revenue $825M
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year. Interferon revenues, including Avonex and Plegridy were $755M in Q1. Tysabri revenues were $463M. Net revenues relating to Rituxan and Gazyva were $331M. Elocate revenues were $54M, Alprolix revenues were $43M.
07:01 EDTBIIBBiogen reports Q1 adjusted EPS $3.82, consensus $3.91
Subscribe for More Information
April 23, 2015
15:07 EDTBIIBBiogen technical comments before earnings
Subscribe for More Information
15:01 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
April 21, 2015
08:52 EDTBIIBBiogen April weekly volatility elevated into Q1 and outlook
Biogen April weekly call option implied volatility is at 74, May is at 35, June is at 32, July is at 31; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 24.
07:31 EDTBIIBBiogen says data presented from ATTAIN study demonstrate efficacy of Plegridy
Subscribe for More Information
April 20, 2015
07:32 EDTBIIBBiogen says new data supports Tecfidera as long-term treatment for MS patients
Subscribe for More Information
07:18 EDTBIIBAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 15, 2015
07:14 EDTBIIBBiogen volatility flat into new drug data
Biogen overall option implied volatility of 35 compares to its 26-week average of 34 according to Track Data, suggesting non-directional into results as shares rally in the preopen on Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis clinical data.
April 14, 2015
18:30 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTBIIBBiogen presents new Anti-LINGO-1 Phase 2 AON data
Subscribe for More Information
11:25 EDTBIIBPTAB declares interference between Forward Pharma and Biogen regarding treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use